Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTC-2111
- Development stage
- Unknown
- Lead developer
- Ponce Aurora
- Modality
- Peptides
- Administration
- Topical
01
Overview
PTC-2111 is a topical geropeptide developed by Ponce Therapeutics (and its affiliate Gerotherapeutix) for cosmetic anti-aging applications. It is a primary active ingredient in the YUUTH™ product line, specifically the YUUTH Full Body Treatment. Powered by MitoXcel™ technology, PTC-2111 is engineered to selectively target and neutralize senescent cells—often referred to as 'zombie cells'—by identifying their characteristically lower mitochondrial membrane potential (ΔΨm). By addressing these cells and the resulting 'inflammaging,' the peptide aims to re-energize and rejuvenate aging skin cells and tissue.
- Brand names
- YUUTH Full Body TreatmentYUUTH
- Other names
- MitoXcel geropeptide
Beyond the preview
Go deeper on PTC-2111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTC-2111.